Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2018 08:00 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results

-- EXPAREL® net product sales of $74.0 million up 9% over prior year first quarter ---- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Pacira...
May 01, 2018 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals to Present at Two Healthcare Conferences in May

PARSIPPANY, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two...
April 26, 2018 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals Announces Timing for First Quarter 2018 Financial Results Webcast and Conference Call

PARSIPPANY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S....
April 06, 2018 17:36 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® as a Nerve Block to Produce Regional Analgesia

EXPAREL is now an opioid-free option for use as an interscalene brachial plexus block for upper extremity surgeries Conference call on Monday, April 9, 2018 at 8:30 a.m. EST PARSIPPANY, N.J., April...
March 06, 2018 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals to Present at the 2018 Barclays Global Healthcare Conference

PARSIPPANY, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to participate in an analyst-led fireside chat at the...
February 28, 2018 08:00 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

-- EXPAREL® net product sales expected to be in the range of $300 to $310 million in 2018 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Pacira...
February 27, 2018 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

University of Tennessee Medical Center at Knoxville, Pacira Pharmaceuticals, and CQ-Insights Announce Collaboration to Minimize Opioid Use After Hernia Surgery

PARSIPPANY, N.J. and KNOXVILLE, Tenn., Feb. 27, 2018 (GLOBE NEWSWIRE) -- To improve patient outcomes and combat a segment of the national opioid epidemic, The University of Tennessee...
February 22, 2018 16:00 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals Announces Timing for 2017 Financial Results Webcast and Conference Call

PARSIPPANY, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2017 financial...
February 16, 2018 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare Conference

PARSIPPANY, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2018 RBC Capital Markets Healthcare...
February 15, 2018 15:34 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia

PARSIPPANY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), announced today that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug...